Literature DB >> 15644390

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.

H Tahir, J Rohrer, A Bhatia, W A Wegener, D A Isenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15644390     DOI： 10.1093/rheumatology/keh533

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  18 in total

1.  The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors:  Beth A Christian; Ming Poi; Jeffrey A Jones; Pierluigi Porcu; Kami Maddocks; Joseph M Flynn; Don M Benson; Mitch A Phelps; Lai Wei; John C Byrd; William A Wegener; David M Goldenberg; Robert A Baiocchi; Kristie A Blum
Journal:  Br J Haematol       Date:  2015-04-07       Impact factor: 6.998

2.  The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.

Authors:  R A Hickman; R Hira-Kazal; C-S Yee; V Toescu; Caroline Gordon
Journal:  Clin Rheumatol       Date:  2015-01-08       Impact factor: 2.980

3.  Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.

Authors:  Christoph T Ellebrecht; Eun J Choi; David M Allman; Donald E Tsai; William A Wegener; David M Goldenberg; Aimee S Payne
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

4.  Repeated B cell depletion in treatment of refractory systemic lupus erythematosus.

Authors:  K P Ng; M J Leandro; J C Edwards; M R Ehrenstein; G Cambridge; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

Review 5.  Rituximab therapy in lupus nephritis: current clinical evidence.

Authors:  Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Soto-Cardenas; Pilar Brito-Zeron; María-José Cuadrado; Giovanni Sanna; Laura Bertolaccini; Munther A Khamashta
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 6.  [Novel B-cell directed strategies for the treatment of rheumatic diseases].

Authors:  I H Tarner
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

7.  Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; Rhona Stein; Chien-Hsing Chang
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

Review 8.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

9.  Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Authors:  Howard A Liebman; Mansoor N Saleh; James B Bussel; O George Negrea; Heather Horne; William A Wegener; David M Goldenberg
Journal:  Haematologica       Date:  2016-08-11       Impact factor: 9.941

10.  Development of antirituximab antibodies in children with nephrotic syndrome.

Authors:  Yo Han Ahn; Hee Gyung Kang; Jiwon M Lee; Hyun Jin Choi; Il-Soo Ha; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2014-03-12       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.